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ABSTRACT
valproic acid (2-n-propylpentanoic acid, vPA), the most widely 
used antiepileptic drug, has potential adverse effects and it 
can disrupt the oxidant and antioxidant balance. Edaravone 
(3-methyl-1-phenyl-2-pyrazoline-5-one, EDA) is a potent free 
radical scavenger. In this study, the effect of EDA on gingiva 
in vPA induced toxicity was investigated. female Sprague 
Dawley rats were randomly divided into four groups: control 
group, EDA (30 mg/kg/day) given group, vPA (0.5 g/kg/day) 
given group,  and vPA+EDA (in same dose and time) given 
group. EDA and vPA were given intraperitoneally for seven 
days. Total protein, lipid peroxidation (LPO), sialic acid (SA) 
and reduced glutathione (GSH) levels and catalase (CAT), 
glutathione-S-transferase (GST), glutathione peroxidase (GPx), 
superoxide dismutase (SOD), myeloperoxidase (mPO), alkaline 
phosphatase (ALP), acid phosphatase (ACP), sodium potassium 
ATPase (na+/K+-ATPase) and tissue factor (Tf) activities were 
determined in gingiva homogenates. The vPA-induced increases 
were statistically significant for mPO (p<0.01), ACP (p<0.01), 
na+/K+-ATPase (p<0.05) and Tf (p<0.01) activities, but not 
for LPO level and ALP activities.  EDA treatment markedly 
blunted all such elevated anomalies. Conclusively, vPA induced 
oxidative and inflammatory gingival tissue damage, reactions 
that were appreciably reversed by concurrent administration of 
EDA. 
Keywords: Gingiva, valproic acid, edaravone,  oxidative stress, 
inflammation 
INTRODUCTION
valproic acid (2-n-propylpentanoic acid, vPA) is the most 
widely used antiepileptic drug in the treatment of certain 
types of seizures (1). Although vPA has good efficacy 
and it is often well tolerated, it has several side effects 
on the neurological,  gastrointestinal, hematological and 
reproductive systems. The most common symptoms of 
vPA toxicity include anorexia, nausea, vomiting and also 
hyperammonemic encephalopathy, pancreatitis, elevated 
liver enzymes, leukopenia, thrombocytopenia, coagulation 
disorders and development of coma (2). The toxicity of vPA 
has been investigated in various studies, but the knowledge 
about the incidence and occurrence of these effects is still 
unclear (3-7). Besides the damage caused to other tissues, 
taking vPA can cause primarily gingival overgrowth and 
other dental problems (8). 
Epilepsy is a chronic neurologic disorder and affects 1-3 % 
of the population. most epilepsy patients receive long-term 
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anticonvulsant therapy and may require medications for 
other transient conditions on body. Both epilepsy and its 
medical management may affect oral health. Therefore, it is 
important to consider the adverse effects of anticonvulsant 
usage on tissues (9). Evidence suggests that the incidence of 
dental disease is increased  in epileptic patients, thus they 
have tendency of dental disease and increased oral health 
needs. The positive correlation between severity of seizure 
and periodontal disease was shown in a study with refractory 
epilepsy patients  (10). 
Edaravone (3-methyl-1-phenyl-2-pyrazoline-5-one, EDA) is 
a potent free radical scavenger, and has been widely used to 
treat acute ischemic stroke. In experimental studies EDA has 
been suggested to show protective effects on inflammation 
and tissue damage by eliminating the deleterious effects of 
oxidants in various tissues (11-13). It acts as an antioxidant 
by quenching hydroxyl radicals and by preventing lipid 
peroxidation caused by hydroxyl radicals. In this study, the 
effect of EDA in vPA induced toxicity was investigated on 
gingiva by some biochemical parameters. 
MATERIAL and METHODS
All experimental protocols were approved by the marmara 
university Animal Care and use Committee (134.2013.
mar). vPA (merck, Germany) and EDA (fluka, Switzerland) 
were dissolved in saline (0.9% naCl) seperately. Thirty seven 
female Sprague Dawley rats were randomly divided into 
four groups as follows; Control group (n=8), EDA (30  mg/
kg/day) given group (n=8), vPA (0.5g/kg/day) given group 
(n=10), vPA + EDA (in the same dose) given group (n=11). 
vPA was given to the animals one hour later than the EDA 
administration everyday. EDA and vPA were administered 
to the experimental group intraperitoneally for 7 days. On 
the 8th day of the experiment, animals were fasted overnight 
and then sacrificed under anesthesia. Gingiva samples were 
homogenized in saline (0.9% naCl) in a bowel filled ice cubes 
for 15 second at high speed by using by Ika- Werkrw-14 
homogenizer to obtain 10% (w/v) homogenates. Oxidant 
and antioxidant parameters; lipid peroxidation (LPO) and 
reduced glutathione (GSH) levels, superoxide dismutase 
(SOD), glutathione-S-transferase (GST), catalase (CAT), 
glutathione peroxidase (GPx) and myeloperoxidase (mPO) 
activities, inflammation, bone resorption and thrombosis 
parameters; sialic acid (SA) levels, na-K ATPase, alkalen 
phosphatase (ALP)-acide phosphatase (ACP), tissue factor 
(Tf) activities were determined in gingiva homogenates.
Determination of total protein 
The method of Lowry (14) was used to determined total 
protein levels of gingiva samples. Briefly, alkali proteins are 
reacted with copper ions and then reduced by folin reactive. 
The absorbance of the product was evaluated at 500 nm 
spectrophotometrically and calculated to express the results 
of the parameters per protein. 
Determination of LPO
malondialdehyte (mDA), results from LPO, was determined 
as thiobarbituric acid reactive substances by the method of 
Yagi (15). The extinction coefficient of 1.56 x 105 m–1cm–1 was 
used and LPO was expressed in terms of mDA equivalents as 
nmol mDA/mg protein.
Determination of  GSH
The method of Beutler (16) was used to determine GSH 
levels of gingiva samples. metaphosphoric acid was used for 
protein precipitation and 5,5′-Dithiobis-2-nitrobenzoic was 
used for color development. for calculation,  the extinction 
coefficient of 1.36 x 104 m–1 cm–1 was used and results were 
expressed as mg GSH/g protein. 
Determination of  SOD activity
The method based on the ability of SOD to increase the effect 
of riboflavin-sensitized photo-oxidation of o-dianisidine 
was used to determine SOD activities in gingiva samples. 
The absorbance of the product was measured in 460 nm 
spectrophotometrically. The net absorbance was calculated by 
measuring absorbances at 0 and 8th minutes of illumunation.
The results were expressed as u/mg protein (17). 
Determination of GST activity
GST is an antioxidant enzyme that catalyzes the conjugation 
of  GSH. The absorbance of the mixture is measured in 
340 nm spectrophotometrically and GST activities were 
calculated by using the extinction coefficient of 9.6 mm-1 cm-1. 
Results were expressed as u/g protein (18). 
Determination of CAT activity 
The method of Aebi (19) was used to determine CAT activities 
of gingiva samples. The method is based on converting 
hydrogen peroxide (H2O2) to water by the effect of CAT. The 
absorbance was measured in 240 nm spectrophotometrically 
and results were expressed as u/mg protein. 
Determination of GPx activity
The method of Paglia and valentine (20) was used to 
determine GPx activities of gingiva samples. Glutathione 
reductase reduced  glutathione disulfide to GSH. During the 
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oxidation of nADPH to nADP, the decreasing absrbance was 
measured in 366 nm spectrophotometrically. for calculation, 
the extinction coefficient of 6.22 mm-1cm-1 was used and 
results were expressed as u/g protein. 
Determination of SA
The method of Warren (21) was used to determine SA 
levels of gingiva samples. The hydrolysate was prepared by 
incubation of the homogenates with 0.1n H2SO4 at 80ºC for 
1 hour. In concentrated phosphoric acid, SA is oxidized with 
sodium periodate and the product of periodate oxidation is 
coupled with thiobarbituric acid. The formed chromophore is 
extracted into cyclohexanone and the absorbances of gingiva 
samples were evaluated in 549 nm spectrophotometrically. 
The results were expressed as mg SA/g protein. 
Determination of MPO activity 
The method of Wei and frenke (22) was used to 
determine mPO activities of gingiva samples. The method 
contains a solution of homogenate, phenol, H2O2 and 
4-Aminoantipyrine.  The change in absorbance of reaction 
mixture  per minute at 460 nm was recorded. The results 
were expressed as u/g protein. 
Determination of ALP and ACP activity
The method of Walter (23) was used to determine ALP and 
ACP activities of gingiva samples. Depending on the pH of the 
medium, ACP and ALP hydrolyze p-nitrophenyl phosphate 
to p-nitrophenol. The absorbances were measured in 405 nm 
spectrophotometrically and ALP and ACP activities were 
expressed as u/g protein. 
Determination of Na+/K+-ATPase activity
The method of Ridderstap (24) was used to determine 
na+/K+-ATPase activities of gingiva samples. The reaction 
solution contained 5 mmol/L KCI, 150 mmol /L naCl, 
2.5 mmol/L mgCl2 and 0.1mmol/L EDTA in 600 ml of 20 
mmol/L imidazole buffer. 0,5 ml of ghost suspension was 
added and the mixture was placed for incubation in 370 for 
10 min. Adding 0.1 ml of 2.5 mmol/L disodium ATP was 
started the reaction. After 1 h, the tubes were cooled and 1ml 
of 15% trichloroacetic acid was added to stop the reaction. 
na+K+ ATPase activities were expressed as mmol Pi/ mg 
protein per hour.
Determination of TF activity
The method of Quick (25) was used to determine Tf activities 
of gingiva samples. Pooled plasma collected from healthy 
subjects was used. The reagents were brought to 37ºC which 
was the reaction temperature. 0.1 ml tissue homogenate 
with 0.1 ml of 0.02 m CaCl2 was mixed and by adding of 0.1 
ml of plasma the clotting reaction being started. Since the 
clotting time is inversely proportional to the Tf activity, 
the lengthening of the clotting time is a manifestation of 
decreased Tf activity. 
STATISTICS
All statistical analyses were performed using SPSS 15.0 
(Statistical Package for the Social Sciences) Software 
program. Results were expressed as mean  standart error 
of the mean (SEm). Groups of data were compared using 
AnOvA followed by Tukey’s multiple comparison tests. p 
<0.05 values were regarded as significant.
RESULTS
Oxidant and antioxidant parameters
The increase in LPO levels of the vPA group was not 
statistically significant (fig.1A). There was a tendency 
towards decreased antioxidant status in vPA group as 
evidenced by unsignificant decreases in GSH levels, SOD, 
CAT, GPx activities compared to controls (fig.1B,1C,1E,1f). 
GST activities decreased significantly (p<0.01) in vPA group 
compared with the control group (fig.1D).  EDA was also 
increased GSH levels, SOD, GST, CAT, GPx activities and 
decreased LPO levels unsignificantly (fig. 1A, 1B,1C,1D,1E, 
1f) .
 
Inflammation, bone resorption and thrombosis parameters
The vPA-induced increases were statistically significant 
for mPO (p<0.01) (fig.2A), ACP (p<0.01) (fig.2B), na+/
K+-ATPase (p<0.05) (fig.2C) and Tf (p<0.01) (fig.2D) 
activities, but not for SA levels (fig.2E) and ALP activities 
(fig.2f) compared to control group. EDA treatment 
markedly blunted all such elevated anomalies. Tf activity was 
expressed as seconds. Shorthened clot formation time shows 
increased Tf activity. EDA treatment caused to significant 
decreases in mPO (p<0.01) (fig.2A), ACP (p<0.01) (fig.2B), 
na+/K+-ATPase (p<0.05) (fig.2C) and Tf activities (p<0.01) 
(fig.2D) in vPA group. EDA was also decreased  SA and ALP 
levels unsignificantly (fig.2E and fig.2f).
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Figure 1. Oxidant and antioxidant parameters in four groups.
values are given as mean±standard error, C: Control group; EDA: Edaravone given group; vPA: valproic acid given group; vPA+EDA: 
valproic acid and edaravone given group; P:protein; LPO: lipid peroxidation; GSH: glutathione; SOD: superoxide dismutase; GST: 
glutathione-S-transferase; CAT: catalase; GPx: glutathione peroxidase. 
**p<0.01 significantly different from group C
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Figure 2. Inflammation, bone resorption and thrombosis parameters in four groups.
values are given as mean±standard error, C: Control group; EDA: Edaravone given group; vPA: valproic acid given group; vPA+EDA: 
valproic acid and edaravone given group; P:protein; mPO: myeloperoxidase; ACP: acid phosphatase; na+/K+ATPase: sodium-potasium 
ATPase; Tf: tissue factor (the lengthening of the clotting time is a manifestation of decreased Tf activity); SA: sialic acid and ALP: alkalen 
phosphatase. 
*p<0.05 , **p<0.01 significantly different from group C; °p<0.05, °°p<0.01 significantly different from group EDA;  +p<0.05, ++p<0.01 
significantly different from group vPA
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DISCUSSION  
vPA is still the broadest spectrum used in antiepileptic drugs 
for all types of seizures in children and adults, although 
serious complications may occur in some patients due to 
toxic side effects of vPA. Gingival enlargement is highly seen 
in patients with gingivitis  and periodontal diseases and is 
a common adverse effect of drugs such as calcium channel 
blockers, anti-convulsants, and immunosuppresants. Sodium 
valproate induced gingival enlargement in a patient with pre-
existing chronic periodontitis has been reported (26). Twenty 
two months old child suffering from gingival enlargement 
following intake of sodium valproate has been reported (27). 
The assosiacion between chronic carbamazepine, valproic 
acid and phenytoin medication on the periodontal condition 
in  epileptic children and adolescents was studied and  it was 
reported that the gingival and sulcus bleeding indices were 
higher in epileptics than in controls, gingival enlargement 
was also found in 30% of the epileptic patients (28). In the 
study of Gurbuz and Tan, epileptic children have been shown 
to possess mental and motor deficits and also these patients 
were at risk for oral health due to side effects of anticonsulvant 
treatment. The dental conditions of epilepsy patients were 
significantly worse than non-epileptic age-matched groups. 
furthermore, poorly controlled epilepsy patients had worse 
oral health compared to patients who had better controlled 
epilepsy (29). 
Disrupted balance between oxidants and antioxidants cause 
oxidative stress, which results in the activation of antioxidant 
system to neutralize the toxicity in the cell. But excessive 
production of reactive oxygen species (ROS) leads to depletion 
of antioxidant enzymes, such as SOD, GST, CAT and GPx. 
These enzymes are part of protection system of the organism 
against harmful effects of ROS by detoxify peroxides. 
Antiepileptic drugs increase ROS by several mechanism 
and cause some damages in certain tissues (2,30,31).  In our 
previous study, significantly decreased GST activities and 
also, although the results were unsignificant, decreased SOD, 
CAT and GPx activities were found in the intestinal tissues 
of vPA group compared to controls (12). The results of this 
study were consisted with the previous studies related with 
the vPA toxicity (32-35). GSH is an effective nonenzymatic 
antioxidant factor in defence system. Although the result 
was unsignificant, decreased GSH level was found in vPA 
treated group compared to controls. Reduced capacity 
of defence system may be a result of decreased levels of 
antioxidants in gingival tissue. Elevation in LPO levels was 
frequently seen in vPA treatment (7,30,35,36), which is an 
evidence of disruption of oxidant-antioxidant balance and 
reduced antioxidant defence by peroxides. In the present 
study, although unsignificantly, increased LPO levels were 
found in vPA group compared to controls. Edaravone was 
an effective agent in eliminating the deleterious effects of 
vPA by increasing antioxidants. unsignificantly decreased 
LPO levels and increased GSH levels and SOD, GST, CAT, 
GPx activities were found in edaravone given vPA groups 
compared to vPA group. unsignificant LPO and GSH results 
may be related with the dose of vPA for the induction of 
damage in gingival tissue.
SA is a member of neuraminic acid derivatives and plays 
a crucial role in metabolic events. Increased levels of SA is 
known as an inflammation marker due to increased levels of 
sialylated acute-phase glycoprotein (37). mPO is an enzyme 
found in polymorphonuclear leucocytes and also used as a 
marker in inflammation. Anticonvulsant drugs may directly 
influence gingival connective tissues by stimulating an 
increase in number of gingival fibroblasts and production 
of connective tissue matrix (38).  The inflammation causing 
the changes in the gingival tissues influence the interaction 
between drug and  fibroblastic activity.  Epithelial width, 
odema, infiltrates of lymphocytes and plasma cells were 
reported (38).  In the present study, increased SA level 
in vPA group may be a protection way of gingival tissue 
and significantly increased mPO activity is an evidence 
of damaged gingival tissue by vPA caused inflammation. 
Oxidative damage, in turn, leads to the generation of oxidized 
molecules, which are bioactive and induce inflammation. 
There is a relationship between oxidative damage and 
inflammation in several stages during the pathogenesis of 
many diseases. The antioxidant effect of EDA and following 
decreasing of inflammation may cause  the decrease in SA 
levels and mPO activities in vPA group.
Epilepsy patients are at risk of fracture due to enzyme-inducing 
antiepileptic drugs. These drugs alter the metabolism and 
cause osteopenia and osteomalacia by leading clearance of 
vitamin D (29). Anticonvulsant drugs cause changes in bone 
metabolism and calcium levels and these drugs may lead to 
a decrease in bone mass (39). In previous studies increased 
ALP activities were reported in serum and different tissues 
(40,41). Consistent with these results, unsignificantly 
increased ALP activity was found in vPA group compared to 
controls. ALP, which is an important enzyme for calcification 
and altered activities can be useful to detect inflammation. 
Edaravone administration reduced ALP activity in vPA 
group in this study. As vPA has been shown to alter bone 
and calcium metabolism, the patients using vPA may have 
special dental needs during treatment. 
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ACP is an enzyme which is widely distributed in tissues. In 
many diseases, especially prostate cancer, diseases of bone, 
diseases of blood increased levels of ACP is found to be 
elevated (42). In the present study, significantly increased 
ACP activity was found in vPA group compared to controls. 
Applying of edaravone was effective in decreasing gingival 
ACP activity in the vPA group. 
na+/K+-ATPase is a membrane bound enzyme and has 
been identified in various human tissues (43). The na+/K+-
ATPase, also known as the na+/K+ pump,  converts the free 
energy of ATP into transmembrane ion gradients. Also, it is 
a signal transducer that modulates cell energy-transducing 
ion pump on the plasma membrane protein. It does not only 
maintains the membrane potential of excitable neuron and 
different cells but also is involved in reabsorption of na+ in 
the kidney (44) and in salivary glands (45). The interaction 
between the inducing drug and the fibroblastic activity is 
influenced by the inflammatory changes within the gingival 
tissues. Increasing gingival fibroblasts DnA synthesis may 
involve stimulation of na+/K+-ATPase activity including 
phosphorylation of na+ channels.  This may be the reason of 
the significant increase of na+/K+-ATPase activity found in 
vPA group compared to controls in the present study. na+/
K+-ATPase activity was decreased in edaravone applied vPA 
group compared to vPA. EDA reversed this increase.
Tf is a cell membrane component. It is a cellular initiator 
of coagulation and many tissues have Tf activity (46-50). 
vPA cause hematological problems and coagulation defects 
are commonly seen in vPA treatment. vPA administration 
significantly increased Tf activity compared to controls and 
decrased Tf activity in gingival tissue was found in edaravone 
given vPA group compared to vPA group. Edaravone may 
be useful in reducing trombosis and coagulation problems. 
CONCLUSION
To our knowledge, there are few reports published on the effects 
of antiepileptic drugs on oral tissues. Dentists should carry 
out dental treatments to epiletic patients under antiepileptic 
drug treatment. Increased oxidant and inflammation marker 
levels and decreased antioxidant enzyme activities suggest 
the damage in gingiva caused by vPA treatment. EDA was 
effective in these parameters and it may be useful to prevent 
side effects of vPA in gingival tissues. EDA can be added to 
the new pharmaceutical formulations and may be used to 
alleviate stomatitis, gingivitis and buccal inflammations in 
dental clinics. However, further investigations in details are 
necessary. 
Edaravon, valproik asit nedeniyle oluşan dişeti 
toksisitesini, oksidatif stresi, inflamasyonu ve doku 
hasarını azaltarak düzeltmektedir
ÖZ
valproik asit (2-n-propilpentanoik asit, vPA) yaygın olarak 
kullanılan antiepileptik ilaçtır,  çeşitli insan ve hayvan 
modellerinde oksidatif etkisi, oksidan ve antioksidan 
dengeyi bozduğunu bildiren bazı araştırmalar vardır. vPA 
gastrointestinal, nörolojik, hematolojik ve üreme sistemleri 
üzerinde potansiyel olumsuz etkilere sahiptir. Edaravone 
(3-metil-1-fenil-2-pirazolin-5-on, EDA) güçlü bir serbest 
radikal temizleyicidir. Bu çalışmada, vPA ile oluşturulan 
toksisite edaravon’un dişeti üzerine etkisi araştırıldı. Sprague 
Dawley dişi sıçanlar rastgele dört gruba ayrıldı: Kontrol grubu, 
EDA (30 mg / kg / gün) verilen grup, vPA (0.5 g / kg / gün) verilen 
grup, vPA + EDA (aynı dozda ve zaman) verilen grup. EDA ve 
vPA yedi gün boyunca intraperitoneal olarak verildi. Deneyin 
8. gününde, tüm hayvanlar gece boyunca aç bırakıldı ve daha 
sonra anestezi altında sakrifiye edildi. Dişeti örnekleri alınarak 
homojenize edildi. Dişeti homojenatlarında total protein, lipid 
peroksidasyon (LPO), siyalik asit (SA) ve indirgenmiş glutatyon 
(GSH) düzeyleri ve katalaz (CAT), glutatyon-S-transferaz 
(GST), glutatyon peroksidaz (GPx), süperoksit dismutaz (SOD), 
miyeloperoksidaz ( mPO), alkali fosfataz (ALP), asit fosfataz 
(ACP), sodyum, potasyum ATPase (na+ / K+ -ATPaz) ve doku 
faktörü (Tf) aktiviteleri tayin edildi. vPA nın oluşturduğu 
artışlar mPO (p<0.01), ACP (p<0.01), na+/K+-ATPaz  (p<0.05) 
ve Tf (p<0.01) aktiviteleri için istatistiksel olarak anlamlı olup, 
LPO seviyesi ve ALP aktivitesi için değildi. EDA verilmesi bu 
anormal artışları anlamlı olarak düzeltmiştir. Sonuç olarak 
vPA’nın oluşturduğu oksidatif ve inflamatuar dişeti hasarı EDA 
verilmesi ile geri döndürülmüştür.
Anahtar kelimeler: Dişeti, valproik asit, edaravon, oksidatif 
stres, inflamasyon
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